Mapping the capacities of fixed health facilities to cover people at risk of gambiense human African trypanosomiasis

Table 2 Number of fixed health facilities providing diagnosis and treatment for gambiense HAT

	Diagnosis					Treatment						Total
	DxC	DxS	DxP	DxPh	Total Dx	Tx1P	Tx2M	Tx2E	Tx2N	Total Tx2	Total Tx
Angola*	19	19	18	17	19	17	12	13	0	13	17	19
Benin	3	3	0	0	3	0	0	0	0	0	0	3
Burkina Faso	2	2	2	1	2	1	1	1	0	1	1	2
Cameroon	8	0	7	7	8	9	6	5	5	6	9	9
Central African Republic	11	9	9	9	11	10	8	7	7	8	10	11
Chad	4	4	4	4	4	10	4	4	4	4	10	10
Congo	10	10	8	7	10	9	5	3	3	5	9	10
Côte d’Ivoire	4	4	1	1	4	4	1	1	1	1	4	4
Democratic Republic of the Congo	524	273	229	173	524	404	147	144	144	147	404	524
Equatorial Guinea	5	1	4	1	5	4	1	1	1	1	4	5
Gabon	1	1	1	1	1	4	2	2	2	2	4	4
Ghana	1	0	0	0	1	1	0	0	0	0	1	1
Guinea	3	2	2	2	3	2	1	1	1	1	2	3
Mali	6	1	1	1	6	1	1	1	1	1	1	6
Nigeria	5	5	5	5	5	5	5	0	0	5	5	5
Sierra Leone	0	0	0	0	0	0	0	0	0	0	0	0
South Sudan	10	6	7	7	10	10	7	7	7	7	10	10
Togo	2	2	0	0	2	0	0	0	0	0	0	2
Uganda	4	4	4	4	4	4	4	4	4	4	4	4
Total	622	346	302	240	622	495	205	194	180	206	495	632

Study area: disease-endemic countries having reporting cases or having conducted active screening activities during the period 2000-2012. DxC: clinical diagnosis; DxS: serological diagnosis; DxP: parasitological diagnosis; DxPh: disease staging. Tx1P: treatment of first-stage infection with pentamidine; Tx2M: treatment of second-stage infection with melarsoprol; Tx2E: treatment of second-stage infection with eflornithine; Tx2N: treatment of second-stage infection with nifurtimox-eflornithine combination therapy (NECT); Tx2: treatment of second stage.
*After closing the study, information was received that Angola upgraded the Tx2E centres to Tx2N.

ISSN: 1476-072X